1,3-dimethoxy-5-(1-methylpropyl)benzene | 67097-04-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,3-dimethoxy-5-(1-methylpropyl)benzene
• 英文别名: 2-(3,5-Dimethoxyphenyl)butan；1-sec-butyl-3,5-dimethoxy-benzene；(+/-)-3.5-Dimethoxy-1-sek.-butyl-benzol；1-sec-Butyl-3,5-dimethoxy-benzol；1-Butan-2-yl-3,5-dimethoxybenzene
• CAS: 67097-04-5
• 化学式: C₁₂H₁₈O₂
• 分子量: 194.274
• InChiKey: BDPYPZNUYAZAMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3-dimethoxy-5-(1-methylpropyl)benzene 在 盐酸 、 乙醚 、 氢碘酸 、 potassium carbonate 、 溶剂黄146 、 丙酮 作用下， 生成 2-sec-butyl-6-hydroxy-4-methoxy-benzaldehyde
  参考文献：
  名称：

  Brown et al., Journal of the Chemical Society, 1949, p. 859,866

  摘要：

  DOI：
• 作为产物：
  描述：

  3,5-二甲氧基苯甲酰氯 在 palladium on activated charcoal 、 乙醚 、 苯 作用下， 生成 1,3-dimethoxy-5-(1-methylpropyl)benzene
  参考文献：
  名称：

  Brown et al., Journal of the Chemical Society, 1949, p. 859,866

  摘要：

  DOI：

文献信息

• Heterocyclic derivatives as modulators of ion channels
  申请人：Martinborough Esther

  公开号：US20080027067A1

  公开（公告）日：2008-01-31

  The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及用作离子通道抑制剂的杂环衍生物。该发明还提供了包括本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• Efficient Pd‐Catalyzed Direct Coupling of Aryl Chlorides with Alkyllithium Reagents
  作者：Thorsten Scherpf、Henning Steinert、Angela Großjohann、Katharina Dilchert、Jens Tappen、Ilja Rodstein、Viktoria H. Gessner

  DOI：10.1002/anie.202008866

  日期：2020.11.9

  organometallic reagents and frequently used in difficult metallation reactions. However, their direct use in the formation of C−C bonds is less established. Although remarkable advances in the coupling of aryllithium compounds have been achieved, Csp2−Csp3 coupling reactions are very limited. Herein, we report the first general protocol for the coupling or aryl chlorides with alkyllithium reagents. Palladium

  有机锂化合物是最重要的有机金属试剂之一，经常用于困难的金属化反应。然而，它们直接用于形成 C−C 键的研究还较少。尽管芳基锂化合物的偶联已取得显着进展，但Csp 2 -Csp 3偶联反应非常有限。在此，我们报告了芳基氯与烷基锂试剂偶联的第一个通用方案。人们发现基于叶立德取代膦（YPhos）的钯催化剂非常适合这种转化，在室温下对各种芳基氯化物具有高选择性，而无需额外的金属转移试剂。这在克级合成中得到了证明，包括材料化学和制药工业的构建模块。此外，芳基锂以及格氏试剂与芳基氯的直接偶联也可以在室温下轻松完成。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• NEGATIVE RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME
  申请人：Shirakawa Koji

  公开号：US20080241745A1

  公开（公告）日：2008-10-02

  A negative resist composition, includes: (A) an alkali-soluble polymer containing a specific repeating unit as defined in the specification; (B) a crosslinking agent capable of crosslinking with the alkali soluble polymer (A) under an action of an acid; (C) a compound capable of generating an acid upon irradiation with actinic rays or radiation; (D) a specific quaternary ammonium salt as defined in the specification; and (E) an organic carboxylic acid, and a pattern forming method uses the composition.
• IL-17A ACTIVITY INHIBITOR AND USE THEREOF
  申请人：TOKAI UNIVERSITY EDUCATIONAL SYSTEM

  公开号：US20200392223A1

  公开（公告）日：2020-12-17

  A low-molecular-weight compound (IL-17 activity inhibitor) having an IL-17 activity-inhibiting ability. The IL-17RA inhibitor is a compound which can bind to interleukin 17 receptor A (IL-17RA) through a non-covalent interaction including at least one intermolecular interaction selected from the group that includes a van der Waals force acting among at least 13 amino acid residues selected from amino acid residues Phe60, Gln87, Asp121, Pro122, Asp123, Gln124, Asp153, Cys154, Glu155, Lys160, Pro164, Cys16 5, Ser167, Ser168, Gly169, Ser170, Leu171, Trp172, Asp173, Pro174, Pro254, Phe256, Ser258, Cys 259, Asp262, Cys263, Leu264 and His266 contained in, for example, an extracellular domain of human IL-17RA and preferably consists of an ionic bond, a hydrogen bond, a CH-π interaction and a hydrophobic interaction each acting among specified amino acid residues among the above-mentioned amino acid residues in a space surrounded by the above-mentioned amino acid residues, and which has an activity to inhibit the binding of interleukin-17A (IL-17A) to IL-17RA originated from human or the like, or a pharmaceutically acceptable salt, solvate or prodrug of the compound.